RLFTY
MindMaze Therapeutics Holding SA engages in the development of AI-powered neurotherapeutics and pharmacological treatments for brain disorders. It focuses on addressing neurological and neuropsychiatric conditions through advanced research, clinical development, and technology-driven solutions. The company is headquartered in Geneva, Switzerland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.43 | -$576,000 | -$3M |
| 2025 Q2 | -0.36 | $1M | -$4M |
| 2024 Q4 | -1.00 | $3M | $250,000 |
| 2024 Q2 | -0.36 | $6M | -$3M |
| 2023 Q4 | -3.32 | $3M | -$7M |
| 2023 Q2 | -5.10 | $3M | -$11M |
| 2022 Q4 | -2.25 | $3M | -$10M |
| 2022 Q2 | -2.55 | $3M | -$15M |